Despite unprecedented clinical activity across multiple types of cancer with programmed death 1 (PD-1)/ligand-1 (PD-L1) blockade therapy, the majority of patients do not respond (primary resistance) or develop resistance after initial tumor regression (acquired resistance)1. This evidence concerns the gene CD274 and cancer.